Brief description not available

Brief description not available

These highly specific biomarkers distinguish potentially malignant mucinous cysts from benign nonmucinous cysts in the pancreas to help diagnose precursor lesions of pancreatic ductal adenocarcinoma. The biomarkers can be detected through enzymatic assays with exceptional accuracy and sensitivity.

This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction. 

This invention describes a robust method to generate functional human beta cell equivalents from pluripotent stem cells in vitro for wide applications in basic research, drug and toxicology screens and as a diabetes cell therapy.

This technology contains a method for modulating the activity of the nuclear receptor LRH-1 with identified small molecule compounds that may be developed to treat inflammatory bowel disease, Type II diabetes, triple negative breast cancer and pancreatic cancer.

Therapeutic inhibitors of Urea Transporter A (UT-A) as highly effective diuretics with reduced risk of cardiac and neurological side effects for treatment of cardiovascular and renal disorders

The invention is a recombinant form of an endogenous protein that can be used to increase fat absorption and modulate gastric motility.

UCSF investigators have identified novel antigens against which immune responses are induced in patients with SLE and type I diabetes. Using a proteomic approach, in addition to detecting autoantibodies to known SLE- or diabetes-associated antigens, the UCSF investigators also identified novel self-antigens that are also associated with the respective disease state. These results could provide novel approaches to the diagnosis and assessment of each of these autoimmune diseases